“Afrigen Biologics has earned SAHPRA’s GMP certification for its Cape Town mRNA facility, enabling it to manufacture investigational biological products for clinical trials. This achievement strengthens Africa’s vaccine manufacturing capacity, enhances pandemic preparedness, and advances the continent’s health sovereignty”
South Africa’s biotechnology industry has reached a defining moment with Afrigen Biologics securing Good Manufacturing Practice (GMP) certification from the South African Health Products Regulatory Authority (SAHPRA). This certification validates Africa’s first end-to-end mRNA manufacturing facility, located in Cape Town, and represents a transformative leap in the continent’s ability to produce advanced vaccines and biologics.
Why GMP Certification Matters
- International Standards: GMP certification ensures that manufacturing processes meet globally recognized quality and safety standards.
- Clinical Trial Readiness: Afrigen can now produce investigational biological products for Phase I and II clinical trials, a critical step toward vaccine innovation.
- Health Sovereignty: By reducing reliance on imports, South Africa strengthens its ability to respond to pandemics and supply vaccines locally.
Background: Lessons from COVID-19
The COVID-19 pandemic exposed Africa’s vulnerability in vaccine access. While wealthy nations secured doses early, African countries faced delays and shortages. This inequity underscored the urgent need for local manufacturing capacity. Afrigen’s facility directly addresses this gap, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset. It provides:
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Voices of Leadership
- Prof. Petro Terblanche (CEO, Afrigen): “This certification is a tribute to the extraordinary commitment of our team. We are ready to support clinical trial production and contribute meaningfully to vaccine development.”
- Dr. Tedros Adhanom Ghebreyesus (WHO Director-General): “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply and Africa’s health sovereignty.”
Economic and Social Impact
- Job Creation: Skilled employment opportunities in biotechnology and pharmaceutical sciences.
- Capacity Building: Training programs for African scientists and technicians.
- Industrial Development: Strengthening South Africa’s position as a biotechnology hub.
Challenges Ahead
- Sustainability: Ensuring long-term funding and operational viability.
- Pipeline Development: Expanding beyond COVID-19 vaccines to other infectious diseases.
- Global Partnerships: Maintaining collaboration with WHO, MPP, and international research institutions.
Future Outlook
Afrigen’s GMP certification signals a new era for African biotechnology. The next phase will focus on:
- Scaling up production capacity.
- Developing a diverse pipeline of mRNA-based vaccines.
- Strengthening partnerships across Africa to ensure equitable distribution.
📊 Key Takeaways
- Afrigen Biologics is now GMP-certified for mRNA manufacturing.
- South Africa becomes Africa’s first country with end-to-end mRNA vaccine production capability.
- Global health equity is advanced by reducing reliance on imports.
- Next steps: Clinical trials, pipeline expansion, and regional distribution.
